Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 193,701 | 200,321 | 241,869 | 241,214 | 212,539 |
| Receivables | 770,776 | 747,605 | 697,843 | 642,881 | 660,452 |
| Inventories | 261,522 | 256,765 | 221,175 | 199,146 | 181,694 |
| Other current assets | 97,087 | 107,456 | 81,703 | 97,311 | 246,828 |
| TOTAL | $1,415,352 | $1,393,086 | $1,333,086 | $1,274,095 | $1,379,040 |
| Non-Current Assets | |||||
| PPE Net | 1,380,568 | 1,383,422 | 1,321,618 | 1,291,068 | 1,175,911 |
| Investments And Advances | 0 | 0 | 0 | 201,352 | 0 |
| Intangibles | 2,834,126 | 2,927,424 | 2,766,701 | 3,773,073 | 2,823,596 |
| Other Non-Current Assets | 1,752,723 | 1,825,429 | 1,653,643 | 484,704 | 1,679,889 |
| TOTAL | $5,967,417 | $6,136,275 | $5,741,962 | $5,750,197 | $5,679,396 |
| Total Assets | $7,382,769 | $7,529,361 | $7,075,049 | $7,024,292 | $7,058,437 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,079 | 2,364 | 2,642 | N/A | 2,275 |
| Accounts payable and accrued liabilities | 181,629 | 211,381 | 225,977 | 198,130 | 127,913 |
| Accrued Expenses | 397,119 | 402,196 | 392,427 | 474,916 | 467,835 |
| Other current liabilities | 181,894 | 190,110 | 144,533 | 140,436 | 163,997 |
| TOTAL | $1,014,194 | $1,048,135 | $993,839 | $1,033,185 | $983,751 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,937,056 | 2,997,221 | 2,676,165 | 2,663,564 | 2,892,676 |
| Deferred Revenues | 251,473 | 242,084 | 228,260 | 219,703 | 221,731 |
| Other Non-Current Liabilities | 601,628 | 599,684 | 556,986 | 546,592 | 489,093 |
| TOTAL | $3,735,837 | $3,828,299 | $3,466,304 | $3,452,125 | $3,642,621 |
| Total Liabilities | $4,750,031 | $4,876,434 | $4,460,143 | $4,485,310 | $4,626,372 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 50,879 | 50,863 | 50,805 | 50,486 | 50,464 |
| Common Shares | 510 | 510 | 509 | 505 | 506 |
| Retained earnings | 1,279,567 | 1,183,094 | 1,073,773 | 980,751 | 878,818 |
| Other shareholders' equity | -390,215 | -253,802 | -170,205 | -160,578 | -127,720 |
| TOTAL | $2,632,738 | $2,652,927 | $2,614,906 | $2,538,982 | $2,432,065 |
| Total Liabilities And Equity | $7,382,769 | $7,529,361 | $7,075,049 | $7,024,292 | $7,058,437 |